Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-Year follow-up from a randomized phase 3 trial (DASISION)

Blood

Volumn 119, Issue 5, 2012, Pages 1123-1129

  Kantarjian, Hagop M ^a   Shah, Neil P ^b   Cortes, Jorge E ^a   Baccarani, Michele ^c   Agarwal, Mohan B ^d   Undurraga, María Soledad ^e   Wang, Jianxiang ^f   Ipiña, Juan Julio Kassack ^g   Kim, Dong Wook ^h   Ogura, Michinori ⁱ   Pavlovsky, Carolina ^j   Junghanss, Christian ^k   Milone, Jorge H ^l   Nicolini, Franck E ^m   Robak, Tadeusz ⁿ   Van Droogenbroeck, Jan ^o   Vellenga, Edo ^p   Bradley Garelik, M Brigid ^q   Zhu, Chao ^q   Hochhaus, Andreas ^r  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d BOMBAY HOSPITAL   (India)

^e HOSPITAL DEL SALVADOR   (Chile)

^f INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^g HOSPITAL GENERAL DE MÉXICO   (Mexico)

^h The Catholic University of Korea   (South Korea)

ⁱ NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^j Fundacion para Combatir La Leucemia   (Argentina)

^k UNIVERSITY OF ROSTOCK   (Germany)

^l HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^m EDOUARD HERRIOT HOSPITAL   (France)

ⁿ MEDICAL UNIVERSITY OF LODZ   (Poland)

^o General Hospital St Jan   (Belgium)

^p UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^q BRISTOL MYERS SQUIBB   (United States)

^r JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BCR ABL PROTEIN; BILIRUBIN; CREATINE KINASE; CREATININE; DASATINIB; IMATINIB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CYTOGENETICS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FLUID RETENTION; FOLLOW UP; GENE MUTATION; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MENINGOENCEPHALITIS; MUSCULOSKELETAL PAIN; MYALGIA; MYOSITIS; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84863011486     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-376087     Document Type: Article

References (30)

1. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1084-1086. (Pubitemid 32267980)
2. Hehlmann R, Saussele S. Treatment of chronic myeloid leukemia in blast crisis. Haematologica. 2008;93(12):1765-1769.
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. (Pubitemid 44903745)
4. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22): Abstract 1126.
5. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358- 3363.
6. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505. (Pubitemid 40740783)
7. Shah NP, Cortes JE, Schiffer CA, et al. Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib [abstract]. J Clin Oncol. 2011;29 (15 suppl):Abstract 6512.
8. Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28(3):398-404.
9. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
10. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850-858. (Pubitemid 28280552)
11. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-1820. (Pubitemid 44394987)
12. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37. (Pubitemid 43990609)
13. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
14. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008;112(4):837-845. (Pubitemid 351240578)
15. Quintas-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113(25):6315-6321.
16. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). Blood. 2010;116(19):3758-3765.
17. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112(12):4437-4444.
18. Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood. 2006;107(11):4250-4256. (Pubitemid 43801348)
19. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11(9):3425-3432. (Pubitemid 40627896)
20. Paschka P, Müller MC, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003;17(9):1687-1694. (Pubitemid 37185241)
21. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7):2332-2338. (Pubitemid 44497517)
22. Müller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009;114(24):4944-4953.
23. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110(12):4005-4011. (Pubitemid 350248456)
24. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007;117(9):2562-2569. (Pubitemid 47494357)
25. Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009;114(10):2168- 2171.
26. Jabbour E, Kantarjian HM, Jones D, et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008;112(13):4839-4842.
27. Khorashad JS, Milojkovic D, Mehta P, et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood. 2008;111(4):2378-2381. (Pubitemid 351451447)
28. Al-Ameri A, Kantarijan H, Borthakur G, et al. Opportunistic infections are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 1120.
29. Al-Ameri A, Kantarijan H, Burton E, et al. Low risk of infectious events in patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) treated with dasatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114 (22):Abstract 3291.
30. Radich JP, Kopecky KJ, Kamel-Reid S, et al. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract LBA6.